Evidence map›Paper›PMID 28911093›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma.

B S Hoppe, C E Hill-Kayser, Y D Tseng, S Flampouri, H M Elmongy, O Cahlon, N P Mendenhall, A Maity, L A McGee, J P Plastaras

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06883604 (Clinical Investigation of PBS Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06883604 narecruitingnot on this mapstarted 2019, after this paper: background citation

Clinical Investigation of PBS Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin

TypeinterventionalSponsorUppsala University HospitalRan2019 to 2041Enrolled75ConditionsHodgkin LymphomaArmsProton therapy.
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.International journal of particle therapy · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

B S HoppeDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville.
C E Hill-KayserDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia.
Y D TsengDepartment of Radiation Oncology, University of Washington, Seattle.
S FlampouriDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville.
H M ElmongyDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia.
O CahlonProton Collaborative Group Registry Membership Site, Warrenville.
N P MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville.
A MaityDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia.
L A McGeeProton Collaborative Group Registry Membership Site, Warrenville.
J P PlastarasDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia.
University of Pennsylvania · USFlorida College · USCollaborative Group (United States) · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated early outcomes for patients receiving chemotherapy followed by consolidative proton therapy (PT) for the treatment of Hodgkin lymphoma (HL). PATIENTS AND

methodsFrom June 2008 through August 2015, 138 patients with HL enrolled on either IRB-approved outcomes tracking protocols or registry studies received consolidative PT. Patients were excluded due to relapsed or refractory disease. Involved-site radiotherapy field designs were used for all patients. Pediatric patients received a median dose of 21 Gy(RBE) [range 15-36 Gy(RBE)]; adult patients received a median dose of 30.6 Gy(RBE) [range, 20-45 Gy(RBE)]. Patients receiving PT were young (median age, 20 years; range 6-57). Overall, 42% were pediatric (≤18 years) and 93% were under the age of 40 years. Thirty-eight percent of patients were male and 62% female. Stage distribution included 73% with I/II and 27% with III/IV disease. Patients predominantly had mediastinal involvement (96%) and bulky disease (57%), whereas 37% had B symptoms. The median follow-up was 32 months (range, 5-92 months).

resultsThe 3-year relapse-free survival rate was 92% for all patients; it was 96% for adults and 87% for pediatric patients (P = 0.18). When evaluated by positron emission tomography/computed tomography scan response at the end of chemotherapy, patients with a partial response had worse 3-year progression-free survival compared with other patients (78% versus 94%; P = 0.0034). No grade 3 radiation-related toxicities have occurred to date.

conclusionConsolidative PT following standard chemotherapy in HL is primarily used in young patients with mediastinal and bulky disease. Early relapse-free survival rates are similar to those reported with photon radiation treatment, and no early grade 3 toxicities have been observed. Continued follow-up to assess late effects is critical.

Indexed as

Proton TherapyAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyChildFemaleHodgkin DiseaseHumansMaleMiddle AgedMultimodal ImagingPositron-Emission TomographyTomography, X-Ray ComputedYoung AdultchemotherapyHodgkin lymphomaproton therapyradiotherapy

Identifiers

PMID28911093
PMCPMC5834068
OpenAlexW2745411417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.